Idraparinux

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Idraparinux
Accession Number
DB06406
Type
Small Molecule
Groups
Investigational
Description
Not Available
Synonyms
Not Available
External IDs
SanOrg 34006 / SR 34006 / SR-34006
Product Ingredients
IngredientUNIICASInChI Key
Idraparinux SodiumH84IXP29FN149920-56-9Not applicable
Categories
UNII
6ADD3H8MFZ
CAS number
162610-17-5
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Investigated for use/treatment in thrombosis, venous thromboembolism, strokes, heart disease, and atrial fibrillation.

Pharmacodynamics
Not Available
Mechanism of action

Idraparinux sodium is a novel long-acting synthetic highly potent synthetic and specific indirect inhibitor of coagulation factor Xa, injectable subcutaneously.

TargetActionsOrganism
UCoagulation factor XNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(1,2,6,7-3H)TestosteroneThe therapeutic efficacy of Idraparinux can be increased when used in combination with (1,2,6,7-3H)Testosterone.
(R)-warfarinThe risk or severity of bleeding can be increased when Idraparinux is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of bleeding can be increased when Idraparinux is combined with (S)-Warfarin.
1-TestosteroneThe therapeutic efficacy of Idraparinux can be increased when used in combination with 1-Testosterone.
18-methyl-19-nortestosteroneThe therapeutic efficacy of Idraparinux can be increased when used in combination with 18-methyl-19-nortestosterone.
4-hydroxycoumarinThe risk or severity of bleeding can be increased when Idraparinux is combined with 4-hydroxycoumarin.
4-HydroxytestosteroneThe therapeutic efficacy of Idraparinux can be increased when used in combination with 4-Hydroxytestosterone.
5beta-dihydrotestosteroneThe therapeutic efficacy of Idraparinux can be increased when used in combination with 5beta-dihydrotestosterone.
AbciximabThe risk or severity of bleeding can be increased when Abciximab is combined with Idraparinux.
AceclofenacThe risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Idraparinux.
Food Interactions
Not Available

References

General References
Not Available
External Links
Wikipedia
Idraparinux

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedNot AvailableDeep Vein Thrombosis (DVT) / Pulmonary Embolism (PE)1
3CompletedTreatmentDeep Venous Thrombosis1
3CompletedTreatmentNonvalvular Atrial Fibrillation1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Serine-type endopeptidase activity
Specific Function
Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting.
Gene Name
F10
Uniprot ID
P00742
Uniprot Name
Coagulation factor X
Molecular Weight
54731.255 Da

Drug created on March 19, 2008 10:29 / Updated on November 02, 2018 09:01